Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000711047 | SCV000841374 | pathogenic | not provided | 2018-05-22 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000711047 | SCV000852905 | likely pathogenic | not provided | 2016-03-11 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000002806 | SCV004295197 | likely pathogenic | Cerebral cavernous malformation 2 | 2023-10-11 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu417Glyfs*3) in the CCM2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 28 amino acid(s) of the CCM2 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with cerebral cavernous malformations (PMID: 14740320). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 585627). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
OMIM | RCV000002806 | SCV000022964 | pathogenic | Cerebral cavernous malformation 2 | 2004-02-01 | no assertion criteria provided | literature only |